Michael S. Ritsner
Sha'ar Menashe Mental Health Center
Mobile Post Hefer 38814
Israel
Name/email consistency: high
- The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care. Ritsner, M.S., Yorkov, V., Ratner, Y., Soifer, P., Gibel, A. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007)
- Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. Ritsner, M., Maayan, R., Gibel, A., Weizman, A. Eur. Neuropsychopharmacol (2007)
- State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients. Ritsner, M., Gibel, A., Maayan, R., Ratner, Y., Ram, E., Modai, I., Weizman, A. Eur. Neuropsychopharmacol (2007)
- Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traits. Ritsner, M.S., Blumenkrantz, H. Psychiatry. Res (2007)
- Predicting quality of life impairment in chronic schizophrenia from cognitive variables. Ritsner, M.S. Qual. Life. Res (2007)
- Positive family history is associated with persistent elevated emotional distress in schizophrenia: evidence from a 16-month follow-up study. Ritsner, M.S., Ratner, Y., Gibel, A., Weizman, R. Psychiatry. Res (2007)
- Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Ritsner, M.S., Gibel, A., Ratner, Y., Tsinovoy, G., Strous, R.D. J. Clin. Psychopharmacol (2006)
- Determinants of changes in perceived quality of life in the course of schizophrenia. Ritsner, M., Gibel, A., Ratner, Y. Qual. Life. Res (2006)
- The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Ritsner, M.S., Gibel, A. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006)
- Coping patterns as a valid presentation of the diversity of coping responses in schizophrenia patients. Ritsner, M.S., Gibel, A., Ponizovsky, A.M., Shinkarenko, E., Ratner, Y., Kurs, R. Psychiatry. Res (2006)
- Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Ritsner, M., Gibel, A., Maayan, R., Ratner, Y., Ram, E., Biadsy, H., Modai, I., Weizman, A. Neuropsychopharmacology (2005)
- Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Ritsner, M., Kurs, R., Ratner, Y., Gibel, A. Psychiatry. Res (2005)
- Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Ritsner, M., Kurs, R., Gibel, A., Ratner, Y., Endicott, J. Qual. Life. Res (2005)
- Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. Ritsner, M., Perelroyzen, G., Ilan, H., Gibel, A. J. Clin. Psychopharmacol (2004)
- Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. Ritsner, M., Gibel, A., Perelroyzen, G., Kurs, R., Jabarin, M., Ratner, Y. J. Clin. Psychopharmacol (2004)
- Temperament types are associated with weak self-construct, elevated distress and emotion-oriented coping in schizophrenia: evidence for a complex vulnerability marker?. Ritsner, M., Susser, E. Psychiatry. Res (2004)